Institut für Transfusionsmedizin und Immunhämatologie
Univ.-Prof. Dr. med. habil. Dr. med. Halvard B. Bönig, M.A.
Arzt für Kinderheilkunde und Jugendmedizin, Arzt für Transfusionsmedizin

Abteilung
Forschung und Entwicklung – Translationale Zelltherapeutikaentwicklung/GMP

Beruflicher Werdegang

1989-1996
Studium der Anglistik, Kunstgeschichte und Medizin an der Heinrich-Heine-Universität Düsseldorf, St. Bartholomew’s Hospital Medical School, London, und University of Tennessee, Memphis TN
 
1995
Magister Artium Anglistik und Kunstgeschichte
 
1996
Med. Staatsexamen
 
1998
Promotion zum Dr. med. an der Medizinischen Fakultät der Heinrich-Heine-Universität Düsseldorf
 
1997-2002
Wissenschaftlicher Mitarbeiter (Arzt in der Weiterbildung) am Zentrum für Kinderheilkunde und Jugendmedizin der HHU Düsseldorf; Facharztprüfung zum Arzt für Kinderheilkunde und Jugendmedizin
 
2002-2004
Senior Research Fellow im Labor von Prof. Papayannopoulou, University of Washington, Seattle, WA
 
2005-2007
Acting Assistant Professor of Medicine/Hematology, University of Washington, Seattle, WA
 
2007-2009
Wissenschaftlicher Mitarbeiter beim DRK-Blutspendedienst BaWüHe, Institut Frankfurt
 
2008-2011
Affiliate Assistant Professor of Medicine/Hematology, University of Washington, Seattle, WA
 
2009-2013
Leiter der Abteilung für Zelltherapeutika / Cell Processing (GMP), Institut für Transfusionsmedizin und Immunhämatologie Frankfurt a.M.
 
seit 2011
Affiliate Associate Professor of Medicine/Hematology, University of Washington, Seattle, WA
 
2012
Ruf (primo loco) auf die W3 Professur für Translationale Entwicklung von Zelltherapeutika an der Goethe Universität, Frankfurt (angenommen)
 
2013
Habilitation im Fach Experimentelle Hämatologie zum Dr. med. habil.
 
2015
Ruf (primo loco) auf die W3 Professur mit Institutsleitung, Institut für Transfusionsmedizin, Otto-von-Guericke Universität Magdeburg (abgelehnt)
 
Aktuell:
Professor (W3) für Translationale Entwicklung von Zelltherapeutika am Institut für Transfusionsmedizin und Immunhämatologie, Fachbereich Medizin, Johann-Wolfgang-Goethe Universität, Frankfurt
Leiter Herstellung Experimentelle Zelltherapeutika und Sachkundige Person, DRK-Blutspendedienst BaWüHe, Institut Frankfurt
 

Mitgliedschaften in wissenschaftlichen Fachgesellschaften (ausgewählt)

  • American Society of Hematology
  • International Society of Experimental Hematology
  • American Association of Blood Banks
  • International Society of Blood Transfusion
     
  • Associate Member Faculty of 1000 (f1000) Hematology

Ausgewählte Publikationen (seit 2013)

  • 64. Muller MM, Bialleck H, Bohmke B, Brauninger S, Varga C, Seidl C, Seifried E, Tonn T, Bonig H (2013) Safety of healthy volunteer stem cell mobilization with Filgrastim G-CSF: Results of a prospective longitudinal five-year follow-up study. Vox Sanguinis 104:46-54
  • 65. Sörensen J, Jarisch A, Smorta C, Köhl U, Bader P, Seifried E, Bonig H (2013) Pediatric apheresis with a novel apheresis device with electronic interface control. Transfusion 53:761-5
  • 66. Bonig H and Papayannopoulou Th (2013) Hematopoietic stem cell mobilization: Updated conceptual renditions. Leukemia 27:24-31
  • 67. Eichler H, Schrezenmeier H, Schallmoser K, Strunk D, Nystedt J, Kaartinen T, Korhonen M, Fleury-Cappellesso S, Sensebé L, Bönig H, Rebulla P, Giordano R, Lecchi L, Takanashi M, Watt SM, Austin EB, Guttridge M, McLaughlin LS, Panzer S, Reesink HW (2013) Donor selection and release criteria of cellular therapy products. Vox Sang. 104:67-91
  • 68. Tramsen L, Schmidt S, Bonig H, Latge Jean-Paul, Lass-Flörl C, Roeger F, Seifried E, Klingebiel T, Lehrnbecher T (2013) Clinical-scale generation of multispecific antifungal T-cells targeting candida, aspergillus and mucormycetes. Cytotherapy 15:344-51
  • 69. Hsieh YT*, Gang EJ*, Geng H, Park E, Huantes S, Chudziak D, Dauber K, Schaefer P, Scharman C, Shimada H, Syedmedi S, Klemm L, Loh M, Kang ES, Koo HH, Hofmann WK, Andrade J, Crooks GM, Willman CL, Müschen M, Papayannopoulou T, Heisterkamp N, Bonig H*, Kim YM* (2013) VLA4 blockade eradicates drug resistant pre-B acute lymphoblastic leukemia. Blood 121:1814-8 *equal contribution Featured in Newswatch, Cancer Discovery January 24, 2013, DOI: 10.1158/2159- 8290.CD-RW2013-019
  • 70. Schulz M, Bug G, Bialleck H, Serve H, Seifried E, Bonig H (2013) Leukodepletion for hyperleukocytosis – first report on a novel technology featuring electronic interphase management. Vox Sanguinis 105:47-53
  • 71. Thorausch K, Schulz M, Bialleck H, Luxembourg B, Seifried E, Bonig H (2013) Feasibility and efficacy of granulocyte apheresis with Spectra Optia IDL. Transfusion 53:3262-8
  • 72. Rettinger E, Bonig H, Wehner S, Lucchini G, Willasch A, Jarisch A, Soerensen J, Esser R, Rossig C, Klingebiel T, Bader P (2013) Feasibility of IL-15- activated cytokine-induced killer cell infusions after haploidentical stem cell transplantation. Bone Marrow Transplant. 48:1141-3
  • 73. Büchner S, Sliva K, Bonig H, Voelker I, Waibler Z, Kirberg H, Schnierle B (2013) Delayed onset of graft versus host disease in immunodeficent HLA-DQ8 transgenic, murine MHC class II deficient mice repopulated by human peripheral blood mononuclear cells. Clinical and Experimental Immunology 173:355-64
  • 74. Karpova D, Wiercinska E, Bonig H (2013) Mobilisierung hämatopoietischer Stammzellen [Mobilization of hematopoietic stem cells]. Transfusionsmedizin 3: 127- 139
  • 75. Kuci Z, Seiberth J, Latifi-Pupovci H, Wehner S, Stein S, Grez M, Bonig H, Köhl U, Klingebiel T, Bader P, Kuci S (2013) Clonal Analysis of Multipotent Stromal Cells Derived from CD271+ Bone Marrow Mononuclear Cells: Functional Heterogeneity and Different Mechanisms of Allosuppression. Hematologica 98:1609- 1616
  • 76. Koeberle V, Pleli T, Schmithals C, Augusto EA, Haupenthal J Bonig H, Peveling-Oberhag J, Miondi RM, Zeuzem S, Kronenberger B, Waidmann O, Piiper A (2013) Cell-free circulating vesicle-associated miRNAs are more stable and more resistant to RNase A treatment than non-vesicle cell-free circulating miRNAs. PLOS ONE 20;8:e75184
  • 77. Karpova D, Dauber K, Spohn G, Chudziak D, Wiercinska E, Schulz M, Pettit AR, Levesque JP, Romagnoli B, Patel K, Chevalier E, Dembowsky K, Bonig H (2013) The novel CXCR4 antagonist POL5551 mobilizes hematopoietic stem and progenitor cells with greater efficiency than Plerixafor. Leukemia 27:2322-2331
  • 78. Hahn S, Sireis W, Hourfar K, Karpova D, Dauber K, Kempf VAJ, Seifried E, Schmidt M, Bonig H (2014) Effects of storage temperature on hematopoietic stability and microbial safety of bone marrow aspirates. Bone Marrow Transplant. 49:338-348
  • 79. Schulz M, Bialleck H, Thorausch K, Bug G, Dunzinger U, Seifried E, Bonig H (2014) Unstimulated leukoapheresis in patients and donors – comparison of two apheresis systems. Transfusion 54:1622-9
  • 80. Rettinger E, Kreyenberg H, Merker M, Kuçi S, Willasch A, Bug G, Ullrich E, Wels WS, Bonig H, Klingebiel T, Bader P. (2014) Immunomagnetic selection or irradiation eliminates alloreactive cells but also reduces anti-tumor potential of cytokine-induced killer cells: implications for unmanipulated cytokine-induced killer cell infusion. Cytotherapy. 16:835-844
  • 81. Preti RA, Chan WS, Kurtzberg J, Dornsife R, Wallace PK, Furlange R, Lin A, Omana-Zapata I, Bonig H, Tonn T (2014) Mutisite evaluation of the novel BD™ stem cell enumeration (SCE) Kit for CD34+ cell enumeration on the BD FACSCanto II™ and BD FACSCalibur™ Flow Cytometers. Cytotherapy 16:1558-74
  • 82. Kolodziej S, Kuvardina ON, Herglotz J, Backert I, Bonig H, Karas M, Proschak E, Lausen J (2014) Influence of PADI4 on histone arginine methylation differentially regulates expression of the Tal1 target genes IL6ST and CTCF. Nature Communications 5:3995
  • 83. Wuchter P, Bieback K, Schrezenmeier H, Bornhäuser M, Müller LP, Bonig H, Wagner W, Meisel R, Paveli P, Tonn T, Lang P, Müller I, Renner M, Malcherek G, Saffrich R, Buss E, Horn P, Rojewski M, Schmitt A, Ho AD, Sanzenbacher R, Schmitt M (2014) Standardization of GMP-compliant production of bone marrow derived human mesenchymal stromal cells (MSCs) for immunotherapeutic applications. Cytotherapy 17:128-39
  • 84. Hsieh YT, Shishido S, Gravey C, Osborne A, Gang EJ, Bonig H, Kim QM (2014) Blockade of integrin-alpha4-mediated adhesion of T-ALL cells. Annals of pediatrics and Child Health 2:1012
  • 85. Shisido S, Bonig H, Kim YM (2014) Role of Integrin Alpha4 in Drug Resistance of Leukemia. Frontiers in Oncology 4:99
  • 86. Belz K, Schoeneberger H, Wehner S, Bonig H, Klingebiel T, Fulda S (2014) Smac mimetic and glucocorticoids synergize to induce apoptosis in childhood ALL by promoting ripoptosome assembly. Blood 124:240-50
  • 87. Hsieh QT, Jiang E, Shisido S, Kim HN, Pham J, Esguerra ZA, Kwok E, Jang J, Bonig H, Biediger RJ, Vanderslice P, Kim QM (2014) Effects of the small-molecule inhibitor of VLA4, TBC3486, on pre-B-ALL cells. Leukemia 28:2101-4
  • 88. Odendahl M, Grigoleit GU, Germeroth L, Neuenhahn M, Albrecht J, Anderl F, Bonig H, Schmitz M, Borhäuser M, Einsele H, Seifried E, Busch DH, Tonn T (2014) Clinical scale isolation of “minimally manipulated” Cytomegalovirus-specific donor lymphocytes for the treatment of refractory Cytomegalovirus disease. Cytotherapy 16:1245-56
  • 89. Bräuninger S*, Thorausch K*, Luxembourg B, Schulz M, Chow K, Seifried E, Bonig H (2014) Deferrals of volunteer stem cell donors referred for evaluation for matched-unrelated stem cell donation. Bone Marrow Transplantation 49:1419-25
  • 90. Klarmann D, Sireis W, Hogardt M, Kempf V, Seifried E, Bonig H (2014) Method (matrix) validation for microbiological control of cellular products. Cell and Tissue Banking 16:311-8
  • 91. Seeger FH, Rasper T, Bonig H, Assmus B, Zeiher AM, Dimmeler S (2014) The Challenges of Autologous Cell Therapy: Systemic Anti-thrombotic Therapies Interfering with Serum Coagulation May Disable Autologous Serum-Containing Cell Products for Therapeutical Use. J Cardiovasc Transl Res. 7:644-50
  • 92. Bonig H, Becker PS, Schwebig A, Turner M (2015) Biosimilar G-CSF for healthy donor stem cell mobilization: need we be afraid? Transfusion 55:430-9 featured in: http://transfusionnews.com/2015/02/15/video-biosimilar-granulocyte- colony-stimulating-factor/ editorial in: Abi-Raad R, Smitch BR: Biosimilar biologics: never identical but close enough. Transfusion 55(2):229–231
  • 93. Chudziak D, Spohn G, Karpova D, Dauber K, Wiercinska E, Miettinen J, Papayannopoulou T, Bonig H (2015) Functional consequences of perturbed CXCL12 signal processing: Analyses of immature hematopoiesis in GRK6-deficient mice. Stem Cells and Development 24:737-46
  • 94. Henrich D, Verboket R, Schaible A, Wilhelm K, Oppermann E, Brune JC, Bonig H, Nau C, Meier S, Marzi I, Seebach C (2015) Characterization of bone marrow mononuclear cells on biomaterials for bone tissue engineering in vitro. BioMed Research International 2015:762407
  • 95. Kays SK, Kaufmann KB, Abel T, Brendel C, Bonig H, Grez M, Buchholz CJ, Kneissl S (2015) CD105 is a surface marker for receptor-targeted gene transfer into human long-term repopulating hematopoietic stem cells. Stem Cells Dev 24:714-23
  • 96. Sorg N, Poppe C, Bunos M, Wingenfeld E, Hümmer C, Krämer A, Stock B, Seifried E, Bonig H (2015) Erythrocyte depletion from bone marrow and peripheral blood buffy coat – a comparison of two new and three established technologies Transfusion 55:1275-82
  • 97. Schönfeld K, Sahm C, Zhang C, Naundorf S, Brendel C, Odendahl M, Nowakowska P, Bonig H, Köhl U, Kloess S, Köhler S, Holtgreve-Grez H, Jauch A, Schmidt M, Kühlcke K, Seifried E, Klingemann HG, Rieger MA, Tonn T, Grez M, Wels WS (2015) Selective Inhibition of Tumor Growth by Clonal NK Cells Expressing an ErbB2/HER2-Specific Antigen Receptor. Mol Ther 23:330-8
  • 98. Bonig H and Kim YM (2015) VLA4 in Acute Lymphoblastic Leukemia; in: Andreeff, M (ed.): Targeted Therapy of Acute myeloid Leukemias, Springer, New York, NY. ISBN: 978-1-4939-1392-3
  • 99. Arnold C, Gispert S, Bonig H, von Wegner F, Somasundaram S, Kell CA (2015) Dopaminergic modulation of cognitive preparation for overt reading: Evidence from the study of genetic polymorphisms. Cerebral Cortex pii: bhu330. [Epub ahead of print]
  • 100. Kraft D, Rall M, Volcic M, Metzler E, Groo A, Stahl A, Bauer L, Nasonova E, Salles D, Taucher-Scholz G, Bonig H, Fournier C, Wiesmüller L (2015) NF-kB- dependent DNA damage-signaling differentially regulates DNA double-strand break repair mechanisms in immature and mature human hematopoietic cells. Leukemia 29:1543-54
  • 101. Seebach C, Henrich D, Schaible A, Relja B, Jugold M, Bonig H, Marzi I. (2015) Cell based therapy by implanted humane bone marrow-derived mononuclear cells (BMC) improved bone healing of large bone defects in rats. Tissue Eng Part A. 21:1565-78
  • 102. Schulz M*, Karpova D*, Spohn G, Damert A, Seifried E, Binder V*, Bonig H* (2015) Variant rs1801157 in the 3’UTR of SDF-1ß does not explain variability of healthy-donor G-CSF responsiveness. PLOSOne 10:e0121859 *equal contribution
  • 103. Zirafi O, Kim KA, Staendker L, Mohr KB, Sauter D, Heigele A, Kluge SF, Wiercinska E, Chudziak D, Richter R, Moepps B, Gierschik P, Vas V, Geiger H, Lamla M, Weil T, Burster T, Zgraja A, Daubeuf F, Frossard N, Hachet-Haas M, Heunisch F, Reichetzeder C, Galzi JL,Castells JP, Canales-Mayordomo A, Jimenez- Barbero J, Gimenez-Gallego G, Schneider M, Shorter J, Telenti A, Hocher B, Forssmann WG, Bonig H, Kirchhoff F, Muench J (2015) Discovery and characterization of an endogenous CXCR4 antagonist. Cell Reports 11:737-47
  • 104. Bunos M, Hümmer C, Wingenfeld E, Sorg N, Seifried E, Bonig H (2015) Automated isolation of primary antigen-specific T-cells from donor lymphocyte concentrates. Vox Sanguinis doi: 10.1111/vox.12291. [Epub ahead of print]
  • 105. Spohn G, Wiercinska E, Karpova D, Bunos M, Hümmer C, Wingenfeld E, Sorg N, Poppe C, Huppert V, Stutz J, Reck K, Essl M, Seifried E, Bonig H (2015) Automated CD34+ cell isolation of peripheral blood stem cell apheresis product. Cytotherapy S1465-3249. [Epub ahead of print]
  • 106. Kuvardina ON, Herglotz J, Kolodziej S, Kohrs N, Herkt S, Wojcik B, Oellerich T, Serve H, Bonig H, Stocking C, Rieger MA, Lausen J (2015) RUNX1 represses the erythroid gene expression program during megakaryocytic differentiation. Blood 125:3570-9
  • 107. Karpova D, Bonig H (2015) CXCR4/CXCL12 signaling in immature hematopoiesis – lessons from pharmacological and genetic models. Stem Cells 33:2391-9
  • 108. Pfirrmann V, Oselsner S, Rettinger E, Huenecke S, Wels WS, Bonig H, Cinatl J, Schubert R, Klingebiel T, Bader P (2015) CMV-specific cytokine-induced killer (CIKp65) cells: Concurrent targeting of leukemia and cytomegalovirus. Cytotherapy 17:1139-51
  • 109. Straetemans T, Grunder C, Heijhuurs S, Hol S, Slaper-Cortenbach I, Bonig H, Sebestyen Z, Kuball J: Untouched GMP-ready purified engineered immune cells to treat cancer. Clin Cancer Res. 21:3957-68
  • 110. Bacher P*, Jochheim-Richter A*, Mockel-Tenbrink N, Kniemeyer O, Wingenfeld E, Alex R, Karpova D, Ortigao A, Lehrnbecher T, Ullman A, Seifried E, Brakhage AA, Assenmacher M, Bonig H*, Scheffold A* (2015) Clinical-scale isolation of the total Aspergillus fumigatus-reactive T helper cell repertoire for adoptive transfer. Cytotherapy S1465-3249. [Epub ahead of print] * contributed equally
  • 111. Chow K, Luxembourg B, Seifried E, Bonig H (2015) Spleen size is significantly influenced by body height and gender: Establishment of normal values for spleen size by ultrasound based on a cohort of 1200 normal healthy individuals. Radiology Oct 28: 150887 (e-pub ahead of print) Featured in: Dtsch Arztebl 2016; 113(4): A-143
  • 112. Latifi-Pupovci H; Kuci Z, Wehner S, Bonig H, Lieberz R, Klingebiel T, Bader P, Kuci S (2015) Wound healing potential of mesenchymal stromal cells generated from human CD271+ bone marrow mononuclear cells. Journal of Translational Medicine (in press)
  • 113. Bremm M, Brehm C, Erben S, Jarisch A, Schumm M, Arendt A, Bonig H, Klingebiel T, Koehl U, Bader P, Huenecke S (2015) Generation and flow cytometric quality control of TCRaß/CD19-depleted grafts. Cytometry Part B (in press)
  • 114. Schulz M and Bonig H (2015) Update on biosimilars of G-CSF – when no news is good news. Current Opinion in Hematology 2016;23:61-6
  • 115. Rall M, Kraft D, Volcic M, Groo A, Nasonova E, Taucher-Scholz G, Bonig H, Wiesmuller L, Fournier C (2015) Impact of charged particle exposure on homologous DNA double-strand break repair in human blood-derived cells. Front Oncol (in press)
  • 116. Rettinger E, Huenecke S, Bonig H, Merker M, Jarisch A, Soerensen J, Willasch A, Bug G, Schulz A, Klingebiel T, Bader P (2016) IL-15-activated cytokine- induced killer cells may sustain remission in leukemia patients after allogeneic stem cell transplantation: feasibility, safety and first insights on efficacy. Hematologica (in press)
  • 117. Winkler IG, Wiercinska E, Barbier V, Nowlan B, Bonig H, Levesque JP (2016) Mobilization of hematopoietic stem cells with highest self-renewal by G-CSF precedes clonogenic cell mobilization peak. Exp Hematol (in press)
  • 118. Assmus B, Alakmeh S, De Rosa S, Bonig H, Hermann E, Levy WC, Dimmeler S, Zeiher AM (2016) Improved outcome with repeated intracoronary injection of bone marrow-derived cells within a registry: rationale for the randomized outcome trial REPEAT. Eur Heart J. [Epub ahead of print]

(zuletzt aktualisiert: Februar 2016)

Univ.-Prof. Dr. med. Halvard B. Bönig, MA

Univ.-Prof. Dr. med. Halvard B. Bönig, MA
Professur für Translationale Entwicklung von Zelltherapeutika

Institut für Transfusionsmedizin und Immunhämatologie Fachbereich Medizin,
Johann-Wolfgang-Goethe Universität
und DRK-Blutspendedienst Baden-Württemberg-Hessen,
Institut Frankfurt am Main
Sandhofstrasse 1
60528 Frankfurt
Tel.: 069 / 6782-177

E-Mail: